Call it bad timing or simple misunderstanding, but investors in Synthetic Biologics Inc. were more focused Monday on the company's disclosure that it voluntarily withdrew its FDA breakthrough therapy designation (BTD) for lead candidate ribaxamase (SYN-004), than for its preliminary accord with the FDA on a proposed design for the planned phase III trial of the agent to prevent Clostridium difficile (C. diff) infection (CDI).